Ann: FDA agrees on potential regulatory pathway f, page-5

re: Ann: FDA agrees on potential regulatory p... Listening in to the teleconference, one key point at the end:
This change of application(from t315i mutation to the larger multiple tki-failure group) means additional work in their submission, but no additional extra costs.
In response to a question he specifically noted they are not looking at a capital raising, have sufficient cash until early next year, but are looking at alternative ways, including some creative ways, to generate additional income.

You can get this online also now it has finished.
Regards.
+7c today... :-)